Identification

Name
Icotinib
Accession Number
DB11737
Type
Small Molecule
Groups
Approved, Investigational
Description

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

Structure
Thumb
Synonyms
  • BPI-2009
External IDs
BPI-2009
Product Ingredients
IngredientUNIICASInChI Key
Icotinib hydrochlorideJTD32I0J831204313-51-8PNNGXMJMUUJHAV-UHFFFAOYSA-N
Categories
UNII
9G6U5L461Q
CAS number
610798-31-7
Weight
Average: 391.427
Monoisotopic: 391.153206168
Chemical Formula
C22H21N3O4
InChI Key
QQLKULDARVNMAL-UHFFFAOYSA-N
InChI
InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
IUPAC Name
N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine
SMILES
C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1

Pharmacology

Indication

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

Structured Indications
Not Available
Pharmacodynamics

In vitro: Icotinib inhibits EGFR activity in a dose-dependent manner, with an IC50 value of 5 nM and complete inhibition at 62.5 nM. Icotinib selectively solely inhibits the EGFR members including the wild type and mutants with inhibition efficacies of 61-99%. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation in human epidermoid carcinoma A431 cells in a dose-dependent manner. Meanwhile, in the proliferation assay performed on A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cell lines, it was found that the relative sensitivity of cell lines to Icotinib is A431 > BGC-823 > A549 > H460 > KB > HCT8 and Bel-7402. Icotinib exhibits a broad spectrum of antitumor activity and it is especially effective against tumors expressing higher levels of EGFR. In vivo: In vivo studies demonstrated that Icotinib exhibited potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug was well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment. A head to head randomized, double blind phase III trial using Gefitinib as an active control for patients with advanced non-small cell lung cancer (NSCLC) was finished recently (Trial registration ID: NCT01040780).

Mechanism of action

Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, preventing completion of the signal transduction cascade. It is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR is an oncogenic driver and patients with somatic mutations, particularly an exon 19 deletion or exon 21 L858R mutation, within the tyrosine kinase domain have activating mutations that lead to unchecked cell proliferation. Over expression of EGFR causes inappropriate activation of the anti-apoptotic Ras signaling pathway, found in many different types of cancer.

TargetActionsOrganism
UEpidermal growth factor receptor
antagonist
Human
Absorption

Bioavailability = 52%

Volume of distribution

the volume of distribution was calculated as Vz/F = 115.00 ± 63.26 l

Protein binding

Icotinib binds to Sudlow's site I in subdomain IIA of Human Serum Albumin (HSA) molecule, resulting in the formation of icotinib-HSA complexes.

Metabolism

Hepatic (mainly CYP3A4, less CYP1A2)

Route of elimination

>90% via faeces, 9% via urine

Half life

5.5 hrs

Clearance

the clearance was calculated as CL/F = 13.30 ± 4.78 l/h

Toxicity

The most common toxicities reported are skin-related events and diarrhea.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Icotinib can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Icotinib can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Icotinib can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Icotinib can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Icotinib can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Icotinib can be decreased when combined with Azithromycin.Approved
BoceprevirThe metabolism of Icotinib can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Icotinib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Icotinib can be decreased when it is combined with Bosentan.Approved, Investigational
CaffeineThe metabolism of Icotinib can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Icotinib can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Icotinib can be increased when it is combined with Ceritinib.Approved
CitalopramThe metabolism of Icotinib can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Icotinib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Icotinib can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Icotinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Icotinib can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Icotinib can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Icotinib can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Icotinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Icotinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Icotinib can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Icotinib can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Icotinib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Icotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Icotinib can be decreased when combined with Delavirdine.Approved
DihydroergotamineThe metabolism of Icotinib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Icotinib can be decreased when combined with Diltiazem.Approved
DosulepinThe metabolism of Icotinib can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Icotinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Icotinib can be decreased when combined with Dronedarone.Approved
EnzalutamideThe serum concentration of Icotinib can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Icotinib can be decreased when combined with Erythromycin.Approved, Vet Approved
FluconazoleThe metabolism of Icotinib can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Icotinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Icotinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Icotinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Icotinib can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Icotinib can be increased when it is combined with Fusidic Acid.Approved
IdelalisibThe serum concentration of Icotinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Icotinib can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Icotinib can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Icotinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Icotinib can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Icotinib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Icotinib can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Icotinib can be decreased when combined with Ketoconazole.Approved, Investigational
LidocaineThe metabolism of Icotinib can be decreased when combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Icotinib can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Icotinib can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Icotinib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Icotinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Icotinib can be increased when combined with Lumacaftor.Approved
MexiletineThe metabolism of Icotinib can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Icotinib can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Icotinib can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Icotinib can be decreased when it is combined with Mitotane.Approved
NefazodoneThe metabolism of Icotinib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Icotinib can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Icotinib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Icotinib can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Icotinib can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Icotinib can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Icotinib can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Icotinib can be increased when it is combined with Palbociclib.Approved
Peginterferon alfa-2bThe serum concentration of Icotinib can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Icotinib can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Icotinib can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Icotinib can be increased when combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Icotinib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Icotinib can be increased when combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Icotinib can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Icotinib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Icotinib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Icotinib can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Icotinib can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe metabolism of Icotinib can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Icotinib can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Icotinib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Icotinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Icotinib can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Icotinib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Icotinib can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Icotinib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Icotinib can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Icotinib can be decreased when combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Icotinib can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Icotinib can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Icotinib can be decreased when combined with Theophylline.Approved
TiclopidineThe metabolism of Icotinib can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Icotinib can be decreased when it is combined with Tocilizumab.Approved
VemurafenibThe serum concentration of Icotinib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Icotinib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Icotinib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Icotinib can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Icotinib can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Icotinib can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
  1. Tan F, Shi Y, Wang Y, Ding L, Yuan X, Sun Y: Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol. 2015;11(3):385-97. doi: 10.2217/fon.14.249. [PubMed:25675121]
  2. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y, Wang Y: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76(2):177-82. doi: 10.1016/j.lungcan.2011.10.023. Epub 2011 Nov 22. [PubMed:22112293]
  3. Liu D, Jiang J, Zhang L, Tan F, Wang Y, Hu P: Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2011 Aug 15;25(15):2131-40. doi: 10.1002/rcm.5061. [PubMed:21732454]
  4. Guan YS, He Q, Li M: Icotinib: activity and clinical application in Chinese patients with lung cancer. Expert Opin Pharmacother. 2014 Apr;15(5):717-28. doi: 10.1517/14656566.2014.890183. Epub 2014 Mar 4. [PubMed:24588695]
  5. Zhang HX, Xiong HX, Li LW: Investigation on the protein-binding properties of icotinib by spectroscopic and molecular modeling method. Spectrochim Acta A Mol Biomol Spectrosc. 2016 May 15;161:88-94. doi: 10.1016/j.saa.2016.02.014. Epub 2016 Feb 23. [PubMed:26963729]
  6. Icotonib approval [Link]
  7. Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer [Link]
  8. Wikipedia [Link]
External Links
PubChem Compound
22024915
PubChem Substance
347828095
ChemSpider
10762174
BindingDB
50391089
ChEMBL
CHEMBL2087361
PharmGKB
PA166114460
Wikipedia
Icotinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentPsoriasis1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentPsoriasis1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
1, 2Unknown StatusTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentLung Cancers / Metastatic Cancers1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Lung / EGFR Positive Non-small Cell Lung Cancer1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentLung carcinoma cell type unspecified stage IV1
2Not Yet RecruitingTreatmentMild to Moderate Psoriasis1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Lung1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Neoplasm, Bronchial / Neoplasms, Lung / Squamous Cell Carcinoma of Lung / Stage IB Non-small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Oesophageal Carcinoma1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)11
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung, Carcinoma1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentNeurofibromatosis Type 2 / Vestibular Schwannomas1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3CompletedTreatmentBrain Metastasis / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3Enrolling by InvitationTreatmentCancers1
3RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3RecruitingTreatmentLung Cancers1
4Active Not RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer1
4Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4Active Not RecruitingTreatmentNeoplasms, Therapy-Associated1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4CompletedTreatmentNeoplasms, Lung1
4RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer2
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
4SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0126 mg/mLALOGPS
logP2.88ALOGPS
logP3.03ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)4.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.73 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity105.82 m3·mol-1ChemAxon
Polarizability42.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Aniline and substituted anilines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Imidolactams / Heteroaromatic compounds / Secondary amines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Acetylides
show 2 more
Substituents
Quinazolinamine / Aniline or substituted anilines / Alkyl aryl ether / Aminopyrimidine / Monocyclic benzene moiety / Pyrimidine / Benzenoid / Imidolactam / Heteroaromatic compound / Dialkyl ether
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da
References
  1. MedChem Express [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wikipedia [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wikipedia [Link]

Drug created on October 20, 2016 14:43 / Updated on November 09, 2017 04:55